Development and evaluation of nanostructured lipid carrier for targeted delivery of gefitinib in breast cancer
Loading...
Date
item.page.authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Breast cancer is the most frequently occurring cancer in women and
newlinestands as the second-leading cause of female mortality. Gefitinib is a tyrosine kinase
newlineinhibitor (TKI) which inhibits the activity of epidermal growth factor receptor
newline(EGFR) in breast cancer.